SpringWorks Therapeutics (NASDAQ:SWTX) – Stock analysts at Wedbush issued their Q1 2021 earnings estimates for shares of SpringWorks Therapeutics in a research note issued on Wednesday, January 15th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.36) per share for the quarter. Wedbush has a “Outperform” rating and a $33.00 price objective on the stock. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2021 earnings at ($0.37) EPS, Q3 2021 earnings at ($0.37) EPS, Q4 2021 earnings at ($0.38) EPS and FY2023 earnings at ($1.10) EPS.
SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($1.30).
SWTX traded up $0.08 during trading on Friday, reaching $35.85. 2,788 shares of the company were exchanged, compared to its average volume of 162,348. The company has a 50-day simple moving average of $32.49. SpringWorks Therapeutics has a 12-month low of $17.02 and a 12-month high of $40.50.
An institutional investor recently bought a new position in SpringWorks Therapeutics stock. Orbimed Advisors LLC bought a new stake in SpringWorks Therapeutics (NASDAQ:SWTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,406,307 shares of the company’s stock, valued at approximately $160,569,000. SpringWorks Therapeutics accounts for about 3.0% of Orbimed Advisors LLC’s portfolio, making the stock its 8th largest position. Orbimed Advisors LLC owned 17.22% of SpringWorks Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 72.13% of the company’s stock.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.
Further Reading: How Investors Can Profit from Options Trading
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.